Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.54 |
| ▸ | FNTB | P49356 | 13/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20657039 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL28193348 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL1529433 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL4025174 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL359894 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL28784346 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL1820771 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL20535484 | 1.00 | FNTA (0.54) | FNTAFNTBALDH1A1MAPTPGGT1B | |
| SCHEMBL11856516 | 0.98 | FNTA (0.51) | FNTAFNTBALDH1A1MAPT | |
| SCHEMBL3860439 | 0.98 | FNTA (0.51) | FNTAFNTBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661413-A1 | BIOMARKERS ASSOCIATED WITH PARKINSON'S DISEASE | Cove Bio LLC (US) | 2020-06-10 | — | — | EP | claimed |
| WO-2019028106-A1 | BIOMARKERS ASSOCIATED WITH PARKINSON'S DISEASE | COVE BIO LLC (US) | 2019-02-07 | — | — | WO | claimed |
| US-6372793-B1 | NERVOUS SYSTEM DISORDERS, METHYLATION DEMETHYLATION FOR NEUROMODULATOR FUNCTIONS | FLORIDA AGRICULTURAL & MECHANICAL UNIVERSITY | 2002-04-16 | — | — | US | claimed |
| EP-3732489-B1 | NOVEL BIOMARKERS AND METHODS FOR DIAGNOSING AND EVALUATING TRAUMATIC BRAIN INJURY | ABBOTT LAB (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240426842-A1 | NOVEL BIOMARKERS AND METHODS FOR DIAGNOSING AND EVALUATING TRAUMATIC BRAIN INJURY | CEDARS-SINAI MEDICAL CENTER | 2024-12-26 | — | — | US | disclosed |
| US-20240366738-A1 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | AGILENT TECHNOLOGIES INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-3240898-B1 | PRENYLCYSTEINE OXIDASE 1 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF OXIDATIVE STRESS-RELATED DEGENERATIVE DISEASES AND PRENYLCYSTEINE OXIDASE 1 AS DIAGNOSTIC MARKER | CENTRO CARDIOLOGICO MONZINO S P A IRCCS (IT) | 2024-08-14 | — | — | EP | disclosed |
| US-11994523-B2 | Biomarkers and methods for diagnosing and evaluating traumatic brain injury | ABBOTT LABORATORIES (US) | 2024-05-28 | — | — | US | disclosed |
| US-11992518-B2 | Molecular vaccines for infectious disease | AGILENT TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-11464784-B2 | Inhibition of aminocylase 3 (AA3) in the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-11 | — | — | US | disclosed |
| US-20210302441-A1 | NOVEL BIOMARKERS AND METHODS FOR DIAGNOSING AND EVALUATING TRAUMATIC BRAIN INJURY | ABBOTT LABORATORIES | 2021-09-30 | — | — | US | disclosed |
| EP-0996441-A1 | PHARMACEUTICAL COMPOSITIONS OF ARGLABIN AND ARGLABIN DERIVATIVES | Paracure, Inc. dba Kazak-Paracure (US) | 2000-05-03 | — | — | EP | disclosed |
| US-6051565-A | Farnesyl-protein transferase inhibitors | INTERNATIONAL PHYTOCHEMISTRY RESEARCH LABS, LTD. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6020365-A | ANTICANCER AGENTS; ANTITUMOR AGENTS | PARACURE, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999043314-A1 | FARNESYL-PROTEIN TRANSFERASE INHIBITORS | INTERNATIONAL PHYTOCHEMISTRY RESEARCH LABS, LTD. (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5902809-A | FARNESYL-PROTEIN TRANSFERASE INHIBITORS; ANTITUMOR AND CARCINOGENIC AGENTS; A SESQUITERPENE LACTONE ISOLATED FROM ARTEMISIA GLABELLA | PARACURE, INC. (US) | 1999-05-11 | — | — | US | disclosed |
| WO-1998056924-A1 | PRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE, DNA ENCODING SAME, AND A METHOD OF SCREENING FOR INHIBITORS THEREOF | NEW YORK UNIVERSITY (US) | 1998-12-17 | — | — | WO | disclosed |
| WO-1998048789-A1 | PHARMACEUTICAL COMPOSITIONS OF ARGLABIN AND ARGLABIN DERIVATIVES | PARACURE, INC. DOING BUSINESS AS KAZAK-PARACURE (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5571687-A | TREATING CELLS WITH SPECIFIED COMPOUNDS TO EFFECT EXPRESSION OF MEMBRANE TRANSPORTER | DUKE UNIVERSITY (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1995033847-A1 | MODULATORS OF MULTIDRUG RESISTANCE TRANSPORTERS | DUKE UNIVERSITY (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464784-B2 | Inhibition of aminocylase 3 (AA3) in the treatment of cancer | PLAAT3, HCCS, LAP3 | FNTA 818/4885FNTB 1127/4885ALDH1A1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.